Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Asthma | 17 | 2021 | 4383 | 2.59 | Why? |
| Anti-Asthmatic Agents | 6 | 2019 | 427 | 2.28 | Why? |
| Anti-Allergic Agents | 3 | 2019 | 167 | 1.25 | Why? |
| Desensitization, Immunologic | 4 | 2021 | 574 | 1.18 | Why? |
| Eosinophils | 4 | 2019 | 848 | 1.00 | Why? |
| Nasal Polyps | 3 | 2018 | 221 | 0.87 | Why? |
| Omalizumab | 3 | 2019 | 158 | 0.76 | Why? |
| Methacholine Chloride | 1 | 2017 | 14 | 0.69 | Why? |
| Leukocyte Count | 2 | 2017 | 3178 | 0.66 | Why? |
| Leukotrienes | 1 | 2016 | 37 | 0.66 | Why? |
| Allergens | 3 | 2018 | 728 | 0.65 | Why? |
| Rhinitis | 3 | 2018 | 626 | 0.64 | Why? |
| Epithelium | 1 | 2018 | 330 | 0.63 | Why? |
| Progesterone | 1 | 2017 | 106 | 0.63 | Why? |
| Gastroesophageal Reflux | 1 | 2016 | 124 | 0.59 | Why? |
| Cysteine | 1 | 2016 | 238 | 0.59 | Why? |
| Rhinitis, Allergic | 2 | 2020 | 704 | 0.57 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.57 | Why? |
| Drug Hypersensitivity | 2 | 2018 | 401 | 0.54 | Why? |
| Immunotherapy | 2 | 2018 | 2421 | 0.53 | Why? |
| Sinusitis | 2 | 2018 | 649 | 0.52 | Why? |
| Exhalation | 1 | 2017 | 441 | 0.50 | Why? |
| Hypersensitivity | 2 | 2020 | 1137 | 0.48 | Why? |
| Immunoglobulin E | 4 | 2019 | 557 | 0.46 | Why? |
| Diagnostic Errors | 1 | 2018 | 865 | 0.46 | Why? |
| Adrenal Cortex Hormones | 2 | 2019 | 6537 | 0.43 | Why? |
| Nitric Oxide | 2 | 2019 | 769 | 0.42 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.37 | Why? |
| Precision Medicine | 4 | 2019 | 1477 | 0.36 | Why? |
| Basophils | 2 | 2018 | 179 | 0.35 | Why? |
| Anaphylaxis | 1 | 2017 | 940 | 0.33 | Why? |
| Interleukin-33 | 2 | 2018 | 120 | 0.31 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.28 | Why? |
| Bronchiectasis | 2 | 2019 | 312 | 0.28 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 3832 | 0.27 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.26 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.26 | Why? |
| Breath Tests | 2 | 2017 | 338 | 0.26 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.24 | Why? |
| Cough | 1 | 2016 | 4891 | 0.24 | Why? |
| Urticaria | 2 | 2018 | 472 | 0.22 | Why? |
| Biomarkers | 7 | 2018 | 23361 | 0.21 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.21 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.20 | Why? |
| Conjunctivitis, Allergic | 1 | 2020 | 94 | 0.19 | Why? |
| Bronchial Provocation Tests | 1 | 2018 | 20 | 0.19 | Why? |
| Receptors, Interleukin | 1 | 2018 | 83 | 0.18 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.18 | Why? |
| Receptors, Cytokine | 1 | 2018 | 75 | 0.18 | Why? |
| Placebo Effect | 1 | 2018 | 108 | 0.17 | Why? |
| Growth Disorders | 1 | 2018 | 91 | 0.17 | Why? |
| Menstruation | 1 | 2017 | 81 | 0.16 | Why? |
| Biological Availability | 1 | 2018 | 388 | 0.16 | Why? |
| Respiratory Function Tests | 3 | 2019 | 1755 | 0.16 | Why? |
| Airway Obstruction | 1 | 2019 | 182 | 0.16 | Why? |
| Hypothalamo-Hypophyseal System | 1 | 2018 | 187 | 0.16 | Why? |
| Chronic Disease | 4 | 2018 | 5139 | 0.15 | Why? |
| Diaphragm | 1 | 2018 | 232 | 0.15 | Why? |
| Angioedema | 1 | 2017 | 111 | 0.14 | Why? |
| Humans | 31 | 2021 | 930598 | 0.13 | Why? |
| Hydrogen-Ion Concentration | 1 | 2016 | 993 | 0.12 | Why? |
| Exosomes | 1 | 2018 | 567 | 0.12 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.12 | Why? |
| Osteoporosis | 1 | 2018 | 410 | 0.12 | Why? |
| Interleukin-17 | 1 | 2016 | 602 | 0.11 | Why? |
| Animals | 8 | 2019 | 78931 | 0.11 | Why? |
| Administration, Inhalation | 1 | 2018 | 1647 | 0.11 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.11 | Why? |
| Exanthema | 1 | 2021 | 1097 | 0.11 | Why? |
| Sleep Apnea, Obstructive | 1 | 2019 | 668 | 0.11 | Why? |
| Pharmacists | 1 | 2021 | 1246 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.10 | Why? |
| Italy | 5 | 2021 | 38444 | 0.10 | Why? |
| Quality of Life | 3 | 2021 | 9820 | 0.10 | Why? |
| Nasal Mucosa | 1 | 2016 | 1218 | 0.09 | Why? |
| Aged | 12 | 2020 | 215776 | 0.09 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.09 | Why? |
| Cytokines | 3 | 2019 | 15010 | 0.08 | Why? |
| Female | 14 | 2021 | 380317 | 0.08 | Why? |
| Adult | 10 | 2020 | 244371 | 0.08 | Why? |
| Inflammation | 3 | 2019 | 13255 | 0.08 | Why? |
| Eye Diseases | 1 | 2018 | 1150 | 0.08 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.08 | Why? |
| Severity of Illness Index | 6 | 2020 | 48226 | 0.08 | Why? |
| Particulate Matter | 1 | 2018 | 3249 | 0.08 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.07 | Why? |
| Male | 12 | 2020 | 367725 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.05 | Why? |
| Adolescent | 4 | 2018 | 86841 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2020 | 6166 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Relaxation Therapy | 1 | 2019 | 112 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Administration, Sublingual | 1 | 2018 | 41 | 0.05 | Why? |
| Neck | 1 | 2021 | 307 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.05 | Why? |
| Albuterol | 1 | 2019 | 105 | 0.04 | Why? |
| Airway Remodeling | 1 | 2019 | 111 | 0.04 | Why? |
| Biomarkers, Pharmacological | 1 | 2018 | 150 | 0.04 | Why? |
| Edema | 1 | 2021 | 333 | 0.04 | Why? |
| Antigens, Dermatophagoides | 1 | 2016 | 25 | 0.04 | Why? |
| Polylysine | 1 | 2016 | 38 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Skin Tests | 1 | 2018 | 229 | 0.04 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.04 | Why? |
| Walk Test | 1 | 2019 | 461 | 0.04 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.04 | Why? |
| Poly I-C | 1 | 2016 | 176 | 0.04 | Why? |
| Muscle Strength | 1 | 2018 | 317 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2019 | 632 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.04 | Why? |
| Placebos | 1 | 2018 | 629 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Culture Media | 1 | 2016 | 366 | 0.03 | Why? |
| Community Pharmacy Services | 1 | 2021 | 426 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Aspergillus fumigatus | 1 | 2016 | 239 | 0.03 | Why? |
| Single-Blind Method | 1 | 2018 | 1283 | 0.03 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.03 | Why? |
| Depression | 1 | 2018 | 14116 | 0.03 | Why? |
| Interleukins | 1 | 2019 | 762 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2021 | 43792 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2019 | 918 | 0.03 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.03 | Why? |
| Patient Education as Topic | 1 | 2019 | 1476 | 0.02 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Drug Approval | 1 | 2018 | 1325 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Emergencies | 1 | 2021 | 4095 | 0.02 | Why? |
| Cells, Cultured | 1 | 2016 | 5835 | 0.02 | Why? |
| Patient Care Team | 1 | 2019 | 3556 | 0.02 | Why? |
| Epithelial Cells | 1 | 2016 | 3508 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2018 | 5993 | 0.01 | Why? |
| Treatment Outcome | 2 | 2019 | 51732 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 7868 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
Heffler's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(154)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(143)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_